骨质疏松症药物对血管和膜化的影响:系统性审查和元分析
Hui Zhen Lo1, Kevin Leow2, Rachael Hii3
1Peninsula Health, 2 Hastings Road, Frankston, VIC, 3199, Australia.
概括
用于减少骨质损失的抗吸收药物,在减少大动脉结石化方面显示出小而不确定的好处. 这些药物没有显著影响血管化,这表明骨质疏松症和血管化途径与这些治疗方法没有完全联系.
科学领域:
- 心血管医学 心血管医学
- 骨的新陈代谢 骨的新陈代谢
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管化与骨矿化有相似之处,但与骨质疏松症有相反的关系.
- 减少骨质损失的药物 (抗吸收药物) 对血管和膜化有不一致的影响.
研究的目的:
- 综合现有的关于抗吸收治疗对骨外 (血管和膜) 化的影响的文献.
- 评估抗吸收药物使用与血管系统和心脏门中的化之间的关联.
主要方法:
- 搜索了Medline和Embase数据库从创立到2024年10月的相关研究.
- 进行了对15项研究 (2344名参与者) 的元分析,使用随机效应模型计算聚合标准化平均差异 (SMD).
- 进行了一次性敏感性分析,以评估发现的内部有效性.
主要成果:
- 抗吸收剂的使用与腹部大动脉化和冠状动脉化无意义的小改善有关.
- 观察到大动脉膜面积显著小幅减少 (表明较少的化) (SMD -0.45,95% CI -0.99至0.08).
- 喷射分数显示出小幅增加 (SMD 0.26,95% CI -0.14至0.66).
结论:
- 抗吸收药物对大动脉狭窄产生了小而积极的影响,但其临床意义仍然不确定.
- 尽管有生物联系,但抗吸收剂似乎没有强烈影响骨外矿化,这表明有不同的潜在途径.
- 需要进一步的研究来阐明血管化和骨质疏松症之间的机制,这些机制独立于抗吸收药物的作用.
相关概念视频
Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
Osteoclasts in Bone Remodeling
2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K
Role of Vitamins in Maintaining Bone Health
3.2K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
3.2K
Antihypertensive Drugs: Action of Calcium Channel Blockers
473
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
473
Bone Remodeling
38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147


